This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-PERMANENT — risk:benefit fails for the canonical archetype.
Desoxyn
SKIP-PERMANENT for users in this archetype.
Aliases (6)
Overview
What is Desoxyn?
Desoxyn is the only FDA-approved methamphetamine pharmaceutical (5 mg tablets), indicated for ADHD and short-term obesity treatment. It is a Schedule II controlled substance with high abuse potential.
Key Benefits
Strong, durable focus and wakefulness; high CNS penetration for ADHD non-responders to amphetamine or methylphenidate. Pharmaceutical-grade, dose-controlled. Used clinically when other stimulants fail or are not tolerated.
Mechanism of Action
Methamphetamine causes phasic and tonic release of dopamine, norepinephrine, and serotonin via reverse transport at DAT/NET/SERT, plus VMAT2 inhibition. The N-methyl group enhances CNS penetration vs amphetamine.
▸Brand options3 known
StatusSchedule II (US DEA) | Schedule II (Canada CDSA) | Class A (UK) | Schedule 8 (Australia) | WADA-banned in-competition (S6 stimulant) | Most countries treat illicit methamphetamine as one of the most heavily controlled substances; pharmaceutical Desoxyn is the same molecule legally distinguished only by source/purity/dose
Peptide Interactions
Smooths anxiety, reduces jaw tension. Same as for amphetamine.
Cardiovascular tolerance support, sleep on dose days.
Cholinergic support, may extend duration of focus.
Speculative neuroprotective adjunct (glutathione precursor, methamphetamine generates oxidative stress) — limited human evidence specifically for methampheta…
Tranylcypromine, phenelzine, isocarboxazid — hypertensive crisis risk, contraindicated. Methamphetamine + MAOI is one of the most dangerous psychopharmacolog…
Even at 1-2.5mg (MAO-B selective range), the combination with methamphetamine is more fraught than with amphetamine. Effective contraindication.
caffeine high-dose, modafinil, methylphenidate — cumulative cardiovascular and dopaminergic load, escalates abuse pattern.
Severe serotonin/dopamine system overload, neurotoxicity multiplier, cardiovascular event risk. The "stim stacking" pattern is the canonical pathway to acute…
Raises methamphetamine levels unpredictably; serotonin component amplified; serotonin syndrome risk.
Serotonin syndrome risk.
Stacked sympathomimetic effects — anxiety, BP spike, arrhythmia risk.
Methamphetamine renal clearance is pH-sensitive (more so than amphetamine in some references) — can cause unpredictable kinetics.
Quality Indicators
Pharmacy-dispensed, intact packaging
Prescription tablets in original sealed packaging from a licensed pharmacy.
Generic vs branded
Generics are usually fine but bioavailability can vary slightly; track if you switch.
Unbranded blister or counterfeit risk
Counterfeit pharmaceuticals are a known issue; verify pharmacy and lot if buying internationally.
What to Expect
- Day 1PK-driven acute peak per administration. Verify dose tolerated.
- Week 1Steady-state reached for most daily-dosed pharma.
- Week 2-4Therapeutic effect established; titration window if needed.
- Long-termPeriodic monitoring per drug class (labs, BP, ECG as applicable).
Side Effects & Safety 20
Side Effects
- 1Reduced appetite — significantly more aggressive than Adderall; major problem for any athlete trying to hit calorie/protein targets
- 2Insomnia — pronounced, even at AM-only dosing
- 3Dry mouth, increased thirst, sweating
- 4Headache — common in first weeks
- 5Increased HR (10-25 bpm) and BP (5-20 mmHg systolic) — substantial cardiovascular load for any chronic athletic training
- 6Anxiety / nervousness / jitteriness / racing thoughts
- 7Irritability and mood swings — especially during comedown
- 8Bruxism / jaw clenching — pronounced, real dental wear concern
- 9Pupil dilation, photophobia
- 10Increased core body temperature — concerning for combat sports training in heat
- 11Palpitations, mild arrhythmias
- 12Tremor, restlessness, motor stereotypies at higher doses
- 13Dizziness, light-headedness on standing
- 14Sustained weight loss (predictable from appetite suppression)
- 15Constipation
- 16Reduced libido (chronic use), erectile dysfunction (dose- and duration-dependent)
- 17Excessive sweating
- 18Skin issues (acne flare from sympathetic activation, rarely Desoxyn-specific eruptions)
- 19Tics or worsening of existing tic disorders
- 20Dependence patterns — earlier and faster than with amphetamine
When to Stop
- Cardiomyopathy / heart failure — class effect, with shorter time-to-event than amphetamine in case-report literature. Particular concern for chronic athletes.
- Sudden cardiac death — extremely rare but real; FDA-class warning. ECG screening before initiation is standard.
- Stroke / MI — rare at therapeutic doses, climbing fast at supratherapeutic
- Amphetamine-induced psychosis — methamphetamine has a higher rate of induced psychosis than amphetamine, partly dose-driven, partly the deeper CNS hit. Family history of psychosis is a strong contraindication.
- Mania / hypomania switch — more common than with amphetamine in undiagnosed bipolar patients
- Serotonin syndrome — possible if combined with MAOIs, certain antidepressants, MDMA
- Dopaminergic terminal neurotoxicity at supratherapeutic doses — the signature methamphetamine neurotoxicity. Reduced DAT density, reduced VMAT2, partial-but-incomplete recovery on abstinence. The therapeutic dose range probably does not produce this damage; the abuse trajectory does. The narrower margin between therapeutic and toxic doses is the single most important reason to skip Desoxyn over Adderall.
- Stimulant use disorder (DSM-5) — actual addiction. Methamphetamine has one of the highest abuse-liability ratings in clinical pharmacology.
- Withdrawal syndrome on discontinuation — fatigue, hypersomnia, depression (often severe), anhedonia, hyperphagia, vivid dreams. Worse and longer than amphetamine withdrawal — acute phase 1-2 weeks, protracted phase 2-3 months for some users.
- Vasculopathy / Raynaud's-like phenomena — same as amphetamine, often more pronounced
- Choreoathetoid movements — at high doses or in susceptible patients
- First 2 weeks: Cardiovascular adjustment (BP, HR), anxiety, sleep impact. The threshold for "this is too much" comes faster than with amphetamine.
- Months 1-3: Tolerance and dose-creep risk. Methamphetamine tolerance develops faster than amphetamine. The temptation to escalate is the start of the abuse trajectory.
- Year 1+: Cardiovascular structural changes (echo if any chest discomfort, palpitations, exercise intolerance); mood baseline drift; cognitive baseline drift. Most prescribers will not run patients on Desoxyn for a year — the drug isn't really used that way.
References
Desoxyn (methamphetamine HCl) — FDA prescribing information
official label, indications (ADHD + exogenous obesity), dosing, warnings.
View StudyMethamphetamine — StatPearls 2024
clinical reference, pharmacology, toxicology.
View StudyWachtel & de Wit 1999 — Subjective and behavioral effects of d-amphetamine vs d-methamphetamine in healthy volunteers
the canonical small-RCT comparison.
View StudyMendelson et al. 2006 — Human pharmacology of methamphetamine
modern PK/PD comparison.
View StudySulzer 2011 — How addictive drugs disrupt presynaptic dopamine neurotransmission
mechanistic synthesis covering methamphetamine vesicular and reverse-transport effects.
View StudyVolkow et al. — PET studies in chronic methamphetamine users
DAT and D2 receptor reductions, partial recovery on abstinence.
View StudyBerman et al. 2009 — Potential adverse effects of amphetamine treatment on brain and behavior: a review
class review including methamphetamine; species-translation caveats.
View StudyRoberts et al. 2020 — Pharmaceutical cognitive enhancement meta-analysis
d-amphetamine no overall significant cognitive enhancement; methodology framework applies to Desoxyn cognitive evidence too.
View StudySmith & Farah 2011 — Are prescription stimulants smart pills?
landmark earlier review; same subjective-objective gap.
View StudyReynolds et al. 2014 / 2015 — Adolescent amphetamine and PFC dopamine connectivity
adolescent-window neurodevelopmental disruption, generalizes class-wise to methamphetamine.
View StudyCruickshank & Dyer 2009 — A review of the clinical pharmacology of methamphetamine
comprehensive clinical review.
View StudyYu et al. 2015 — Methamphetamine-induced cardiovascular toxicity
cardiotoxicity mechanism review.
View StudyUSAF Aerospace Medicine — Pharmacological cognitive enhancement studies (1990s-2000s)
operational vigilance research that informed military "go-pill" choices.
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.